{
    "Clinical Trial ID": "NCT00574587",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Stratum A: VR-Paclitaxel-Trastuzumab",
        "  Stratum A: Vorinostat 200 (Dose Level 1) or 300 mg (Dose level 2) by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks, followed by surgery",
        "INTERVENTION 2: ",
        "  Stratum B: VR-Paclitaxel-Trastuzumab",
        "  Stratum B: 300 mg by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks, followed by surgery"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed adenocarcinoma of the breast associated with the following stages: IIB, IIIA, IIIB or IIIC.",
        "  Tumor must be Her2/neu positive",
        "  No prior chemotherapy, radiation or definitive therapeutic surgery",
        "Exclusion Criteria:",
        "  May not be receiving any other investigational agents",
        "  Uncontrolled intercurrent illness"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab",
        "  Dose limiting toxicity in cycle 1",
        "  Time frame: 3 weeks",
        "Results 1: ",
        "  Arm/Group Title: Stratum A: VR-Paclitaxel-Trastuzumab",
        "  Arm/Group Description: Stratum A: Vorinostat 200 (Dose Level 1) or 300 mg (Dose level 2) by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks, followed by surgery",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: mg  300",
        "Results 2: ",
        "  Arm/Group Title: Stratum B: VR-Paclitaxel-Trastuzumab",
        "  Arm/Group Description: Stratum B: 300 mg by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks, followed by surgery",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: mg  300"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/3 (0.00%)",
        "  cardiac tamponade 0/3 (0.00%)",
        "  congestive heart failure 0/3 (0.00%)",
        "  pulmonary emobolism 0/3 (0.00%)",
        "Adverse Events 2:",
        "  Total: 2/23 (8.70%)",
        "  cardiac tamponade 0/23 (0.00%)",
        "  congestive heart failure 1/23 (4.35%)",
        "  pulmonary emobolism 1/23 (4.35%)"
    ]
}